Skip to main content
$15.10 -0.28 (-1.82%) At close · Jul 24
Market Cap
$256.89M
Shares
16.96M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$53.74M
FY2025 Revenue FY2018–FY2025
Net Income
$29.82M +162.5%
FY2025 Net Income FY2018–FY2025
Operating Margin
31.45%
FY2025 Operating Margin FY2018–FY2025
Diluted EPS
$2.42 +136.8%
FY2025 Diluted EPS FY2022–FY2025
Operating Cash Flow
-$33.54M +50.5%
FY2025 Operating Cash Flow FY2018–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
$53.74M $0 $1.16M $3.21M $33.97M $2.7M $1.67M $3.68M
$1.23M $1.06M $2.83M
$15.25M $19.16M $48.14M $62M $98.35M $93.09M $100.39M $89.4M $47.95M
$17.08M $17.68M $17.96M $31.26M $38.14M $36.84M $32.57M $22.21M $17.3M
$10.28M
$32.33M $36.84M $66.1M $102.59M $136.49M $129.92M $132.97M $111.61M $65.25M
$21.41M $16.9M -$66.1M -$101.43M -$133.28M -$95.95M -$130.26M -$109.94M -$61.56M
31.45% -8774.13% -4154.64% -282.44% -4820.98% -6599.22% -1671.12%
$11.84M $12.92M $20.02M $14.35M $134.48M $185K $1.57M $6.03M $4.35M
$0 -$1.63M
$29.82M -$46.09M -$87.08M $1.2M
$0 $0 $21K $0 $715K $0 $0 $0 $0
-$7.61M $29.82M -$47.73M -$112.96M -$5.01M -$95.76M -$128.69M -$103.92M -$57.22M
55.49% -9771.71% -156.02% -281.9% -4762.92% -6237.45% -1553.07%
$3.45M $29.82K -$47.73K
$29.82M -$47.73M -$112.56M -$5.4M -$95.77M -$128.88M -$103.66M -$57.22M
USD/shares $2.42 -$5.12 -$35.10 -$1.62
USD/shares $2.42 -$6.58 -$35.10 -$1.62
shares 12.3M 9.32M 3.21M 3.19M 3.07M 2.55M 2.34M 1.59M
shares 12.31M 9.66M 3.21M 3.19M 3.07M 2.55M 2.34M 1.59M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.41×
EV/EBIT
Biotechnology median 26.60×
P/E (TTM)
5.45×
Biotechnology median 7.07×

Valuation over time computed as of each quarter's filing date

Key facts CIK 1661998 CUSIP 746964105 13F (30d) 6 filings 6 filers Visit website Investor relations